Yunnan Baiyao: INB301 Injection Approved for Clinical Trials

Yunnan Baiyao Announcement: The company recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration (Notification No.: 2026LP01002). After review, the clinical trial application for INB301 injection, accepted on February 24, 2026, meets the relevant requirements for drug registration. The trial for tumor cachexia is approved to proceed.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin